References
- Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loeffler JP, Martin J, et al. Guidelines for the preclinical in vivo evaluation of pharmacologically active drugs for ALS/MND: report on the 142nd ENMC International Workshop. Amyotroph Lateral Scler. 2007; 8: 217–23
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008; 319: 1668–72
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, et al. TAR-DBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 572–4
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006; 314: 130–3
- Kwiatkowski TJ, Bosco JD, LeClerc AD, Tamrazian E, van den Berg CR, Russ C, et al. Science. 2009; 323: 1205–8
- Vance C, Rogelj B, Hortobágyi T, de Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in Fus, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009; 323: 1208–11
- Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994; 264: 1772–5
- Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14: 1105–16
- Laird FM, Farah MH, Ackerley S, Hoke A, Maragakis N, Rothstein JD, et al. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci. 2008; 28: 1997–2005
- Rothstein JD. Of mice and man: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003; 53: 423–6
- Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007; 26: 1–13
- Schnabel J. Standard Model. Nature. 2008; 445: 682–5
- Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008; 9: 4–15
- Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF, et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol. 2005; 58: 258–65
- Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008; 105: 2052–7
- Pizzasegola C, Caron L, Daleno C, Ronchi A, Minoia C, Carri MT, et al. Treatment with lithium carbonate does not improve disease progression in two different strains of 5001 mutant mice. Amyotroph Lateral Scler. 2009; 10: 221–28
- Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the Fus about TDP-43. Cell. 2009; 136: 1001–4
- Angelov DN, Waibel S, Guntinals-Lichius O, Lenzen M, Neiss WF, Tomov TL, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2003; 100: 4790–5
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. for the Amyotrophic Lateral Sclerosis/Riluzole Study Group-II. Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996; 347: 1425–31